COMMUNIQUÉS West-GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
09/04/2026
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
The Growing Connection Between Microplastics and the Human Heart
09/04/2026
Anathapindika Founder Speaks to Need for Detoxification in Supplementation: “Adding More Nutrients to Our Diets Is Not Enough for Healthy Living” Fort Lauderdale, FL, April 09, 2026 (GLOBE NEWSWIRE) -- The presence of [...]
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
09/04/2026
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups Azenosertib therapeutic profile [...]
BCAN Names Ferring Pharmaceuticals and the Astellas/Pfizer Alliance as National Presenting Sponsors of the 2026 Walks to End Bladder Cancer
09/04/2026
Partnerships fuel awareness, research and support for people impacted by bladder cancer Bethesda, MD, April 09, 2026 (GLOBE NEWSWIRE) -- The Bladder Cancer Advocacy Network (BCAN) today announced that Ferring [...]
Curonix LLC Announces Appointment of Don Payerle to its Board of Managers, Strengthening Strategic Leadership
09/04/2026
POMPANO BEACH, Fla., April 09, 2026 (GLOBE NEWSWIRE) -- Curonix LLC, a leading medical technology company dedicated to relieving chronic pain, today announced the appointment of Don Payerle, a seasoned healthcare [...]
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
09/04/2026
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SOUTH SAN FRANCISCO, [...]
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
09/04/2026
RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S [...]
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
09/04/2026
Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s third major pharma [...]
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
09/04/2026
The financing combines a $50M Series D investment by Boehringer Ingelheim with additional dedicated funding to support commercialization. As part of the agreement, Boehringer is transferring responsibility for [...]
Soleo Health Opens New Ambulatory Infusion Center in Austin, Texas
09/04/2026
FRISCO, Texas and AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today the opening of its new ambulatory [...]
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
09/04/2026
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer Preclinical characterization of FHT-171, [...]
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
09/04/2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
09/04/2026
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to [...]
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
09/04/2026
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
09/04/2026
NANJING, China, April 09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig ( [...]
Losing Your Voice? Millions Experience Persistent Problems Each Year
09/04/2026
ASHA Shares Warning Signs of Voice Disorders and Tips To Protect Your Voice for World Voice Day Rockville, MD, April 09, 2026 (GLOBE NEWSWIRE) -- Most people will experience an occasional sore throat related to a cold [...]
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
09/04/2026
• Ecuador aims to become one of the first rabies free countries in Latin America. • Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological surveillance. • Boehringer [...]
Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
09/04/2026
First patient dosed in France, expanding the DOMISOL study beyond Australia DT ‑ 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program MONTREAL and [...]
Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
09/04/2026
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain cancer model that [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum